Skip to main content
Erschienen in: Annals of Hematology 11/2022

26.09.2022 | Letter to the Editor

CALR loss-of-heterozygosity as a potential driver for extramedullary AML

verfasst von: Marie-Christine Weller, Eugenia Haralambieva, Marco Matteo Bühler, Rudolf Benz, Alexandre Pierre André Theocharides, Stefan Balabanov

Erschienen in: Annals of Hematology | Ausgabe 11/2022

Einloggen, um Zugang zu erhalten

Excerpt

Dear Editor, …
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Dohner H, Estey E, Grimwade D et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447CrossRef Dohner H, Estey E, Grimwade D et al (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129(4):424–447CrossRef
2.
Zurück zum Zitat de Guzman CG, Warren AJ, Zhang Z et al (2002) Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation. Mol Cell Biol 22(15):5506–5517CrossRef de Guzman CG, Warren AJ, Zhang Z et al (2002) Hematopoietic stem cell expansion and distinct myeloid developmental abnormalities in a murine model of the AML1-ETO translocation. Mol Cell Biol 22(15):5506–5517CrossRef
3.
Zurück zum Zitat Yuan Y, Zhou L, Miyamoto T et al (2001) AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci USA 98(18):10398–10403CrossRef Yuan Y, Zhou L, Miyamoto T et al (2001) AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci USA 98(18):10398–10403CrossRef
4.
Zurück zum Zitat Klampfl T, Gisslinger H, Harutyunyan AS et al (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369(25):2379–2390CrossRef Klampfl T, Gisslinger H, Harutyunyan AS et al (2013) Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 369(25):2379–2390CrossRef
5.
Zurück zum Zitat Nangalia J, Massie CE, Baxter EJ et al (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369(25):2391–2405CrossRef Nangalia J, Massie CE, Baxter EJ et al (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369(25):2391–2405CrossRef
6.
Zurück zum Zitat Heuser M, Panagiota V, Koenecke C et al (2014) Low frequency of calreticulin mutations in MDS patients. Leukemia 28(9):1933–1934CrossRef Heuser M, Panagiota V, Koenecke C et al (2014) Low frequency of calreticulin mutations in MDS patients. Leukemia 28(9):1933–1934CrossRef
7.
Zurück zum Zitat Theocharides AP, Lundberg P, Lakkaraju AK et al (2016) Homozygous calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency. Blood 127(25):3253–3259CrossRef Theocharides AP, Lundberg P, Lakkaraju AK et al (2016) Homozygous calreticulin mutations in patients with myelofibrosis lead to acquired myeloperoxidase deficiency. Blood 127(25):3253–3259CrossRef
8.
Zurück zum Zitat Shahin OA, Ravandi F (2020) Myeloid sarcoma. Curr Opin Hematol 27(2):88–94CrossRef Shahin OA, Ravandi F (2020) Myeloid sarcoma. Curr Opin Hematol 27(2):88–94CrossRef
9.
Zurück zum Zitat Pileri SA, Ascani S, Cox MC et al (2007) Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia 21(2):340–350CrossRef Pileri SA, Ascani S, Cox MC et al (2007) Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia 21(2):340–350CrossRef
10.
Zurück zum Zitat Shide K, Kameda T, Kamiunten A et al (2020) Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms in mice. Blood 136(1):106–118PubMedPubMedCentral Shide K, Kameda T, Kamiunten A et al (2020) Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms in mice. Blood 136(1):106–118PubMedPubMedCentral
Metadaten
Titel
CALR loss-of-heterozygosity as a potential driver for extramedullary AML
verfasst von
Marie-Christine Weller
Eugenia Haralambieva
Marco Matteo Bühler
Rudolf Benz
Alexandre Pierre André Theocharides
Stefan Balabanov
Publikationsdatum
26.09.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 11/2022
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-022-04976-8

Weitere Artikel der Ausgabe 11/2022

Annals of Hematology 11/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.